

# **Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Pipeline Review, H1 2018**

<https://marketpublishers.com/r/PC425C2FFAEEN.html>

Date: April 2018

Pages: 94

Price: US\$ 3,500.00 (Single User License)

ID: PC425C2FFAEEN

## **Abstracts**

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Pipeline Review, H1 2018

### **SUMMARY**

According to the recently published report 'Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform - Pipeline Review, H1 2018'; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) pipeline Target constitutes close to 21 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein

Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - The phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha also called p110 $\alpha$  is a protein encoded by the PIK3CA gene.

It is involved in cell growth, survival, proliferation, motility and morphology. It participates in cellular signaling in response to various growth factors. It is involved in the activation of AKT1 and signaling via insulin receptor substrate (IRS) proteins. It is essential in endothelial cell migration during vascular development through VEGFA signaling. It is required for lymphatic vasculature development.

The report 'Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform - Pipeline Review, H1 2018' outlays comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics development with respective active and dormant or discontinued projects.

Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 3 and 9 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Dermatology, Ophthalmology and Respiratory which include indications Metastatic Breast Cancer, Solid Tumor, Breast Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Multiple Myeloma (Kahler Disease), Ovarian Cancer, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Pancreatic Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Thyroid Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Thyroid Cancer,

B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, CNS Lymphoma, Colon Cancer, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Stromal Tumor (GIST), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Lung Cancer, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Mantle Cell Lymphoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Myelofibrosis, Non-Small Cell Lung Carcinoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Ductal Adenocarcinoma, Papillary Thyroid Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary CNS Lymphoma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Carcinoma, Thrombocytopenia Myelofibrosis, Thymoma (Thymic Epithelial Tumor) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153)

The report reviews Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics and enlists all their major and minor projects

The report assesses Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit

Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Overview

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Companies Involved in Therapeutics Development

Advenchen Laboratories LLC

AstraZeneca Plc

Bayer AG

Curis Inc

Eli Lilly and Co

Genentech Inc

GlaxoSmithKline Plc

Millennium Pharmaceuticals Inc

Novartis AG

Onconova Therapeutics Inc

PIQUR Therapeutics AG

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform

(Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or

Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein

Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Drug Profiles

AL-58922 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alpelisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1082439 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimiralisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buparlisib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fimepinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GDC-0077 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HHCYH-33 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3023414 - Drug Profile



Product Description

Mechanism Of Action

R&D Progress

NSC-765844 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omipalisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-146040 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PQR-514 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PQR-530 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

serabelisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-2523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PI3K Alpha for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Pan PI3K for Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress



## Small Molecules to Inhibit PI3K Alpha for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPR-965 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

taselisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Dormant Products

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Discontinued Products

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Product Development Milestones

Featured News & Press Releases

Dec 01, 2017: Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition

Nov 14, 2017: Novartis to Present Data on Alpelisib (BYL719) at Upcoming 40th annual San Antonio Breast Cancer Symposium (SABCS)

Sep 25, 2017: SignalRx Presents in silico Design of Dual PI3K/BRD4 Inhibitors for Combinatorial Activation of Anti-tumor Immunity in Treating Cancer

Sep 08, 2017: LORELEI: Taselisib Boosts Breast Tumor Shrinkage

May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting

May 01, 2017: SignalRx Discloses its Novel Immuno-Oncology Program Approach at the 12th Annual Drug Discovery Chemistry 2017 Meeting

Apr 27, 2017: PIQUR Receives EMA Orphan Drug Designation for PQR309 in Diffuse Large B-Cell Lymphoma

Feb 01, 2017: SignalRx Pharmaceuticals Announces Breakthrough Results on Novel Anti-Cancer Dual PI3K-BRD4 Inhibition Paradigm in PNAS Publication

Dec 12, 2016: PI3K Inhibitor Buparlisib in Combination with Fulvestrant Prolongs PFS Compared to Placebo Plus Fulvestrant

Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association

Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting

Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting

Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology

Jan 11, 2016: Seahorse Bioscience XF Technology Reaches 500th Citation in Cancer Research

Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Indications, H1 2018  
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018 (Contd.1), H1 2018  
Products under Development by Companies, H1 2018 (Contd.2), H1 2018  
Products under Development by Companies, H1 2018 (Contd.3), H1 2018  
Products under Development by Companies, H1 2018 (Contd.4), H1 2018  
Number of Products under Investigation by Universities/Institutes, H1 2018  
Products under Investigation by Universities/Institutes, H1 2018  
Number of Products by Stage and Mechanism of Actions, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Pipeline by Advenchen Laboratories LLC, H1 2018  
Pipeline by AstraZeneca Plc, H1 2018  
Pipeline by Bayer AG, H1 2018  
Pipeline by Curis Inc, H1 2018  
Pipeline by Eli Lilly and Co, H1 2018  
Pipeline by Genentech Inc, H1 2018  
Pipeline by GlaxoSmithKline Plc, H1 2018  
Pipeline by Millennium Pharmaceuticals Inc, H1 2018  
Pipeline by Novartis AG, H1 2018  
Pipeline by Onconova Therapeutics Inc, H1 2018  
Pipeline by PIQUR Therapeutics AG, H1 2018  
Dormant Products, H1 2018  
Dormant Products, H1 2018 (Contd.1), H1 2018  
Discontinued Products, H1 2018  
Discontinued Products, H1 2018 (Contd.1), H1 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

### COMPANIES MENTIONED

Advenchen Laboratories LLC

AstraZeneca Plc

Bayer AG

Curis Inc

Eli Lilly and Co

Genentech Inc

GlaxoSmithKline Plc

Millennium Pharmaceuticals Inc

Novartis AG

Onconova Therapeutics Inc

PIQUR Therapeutics AG

## I would like to order

Product name: Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform  
(Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or  
Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein  
Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/PC425C2FFAEEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer  
Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click  
button on product page <https://marketpublishers.com/r/PC425C2FFAEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form  
below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms  
& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970